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Abstract 
Introduction  
Patients with advanced chronic kidney disease (CKD) on haemodialysis (HD) may have 
increased C reactive protein (CRP) values and depressive symptoms. There is debate 
about the strength and nature of previously reported associations. We investigated 
these issues in a cohort of patients on HD. 
Methods 
We screened for depressive symptoms using two valadiated depression screening tools: 
the Beck Depression Inventory-II (BDI-II), Patient Health Questionnaire (PHQ-9). 
Demographic and clinical correlates of depression symptoms were eveluated in adjusted 
linear and logistic regression models, which included extra renal comorbidity and high 
CRP (>5 mg/L). 
Findings 
396 HD patients were studied; 63.1% male, mean age 63.1 ±16.4 years, median CRP 6 (5-
15) mg/l. Depression scores were similar in those with normal and high CRP (BDI-II 
(9(5-17) vs 11(6-20)) or PHQ (4(2-9) vs 6(2-10)). In adjusted multivariable regression 
BDI-II scores were associated with previous history of depression (β 10.8, p<0.001), 
serum albumin (β 0.41, p<0.001), anuria (β 2.4, p<0.037), diabetes (β 2.7, p=0.033) and 
age (β -0.10, p=0.009). High CRP was not independently associated with BDI-II (β 2.20, 
p=0.057), though was with PHQ-9 (β 1.20, p=0.046).  In logistic regression those with 
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high CRP were 1.9 times more likely to score ≥16 on BDI-II screening (p=0.016), but did 
not relate significantly to a PHQ-score ≥10. 
 
Discussion 
A relationship was observed between CRP and depression symptoms, though the effect 
was small, of unlikely clinical significance, and inconsistent between depression 
measures. Previous reports of this association may reflect overlap between symptoms  
of depression and advanced CKD. 
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Introduction 
Major depressive and mood affective disorders are more common in patients 
with chronic diseases. As many chronic diseases, such as cancer, rheumatoid arthritis, 
chronic pulmonary disease and heart failure are associated with elevated markers of 
systemic inflammation, an association between depressive illnesses and mood affective 
disorders and markers of systemic inflammation have been recognised for some years 
[1].The capillaries at the base of the median eminence are fenestrated, allowing direct 
passage of circulating cytokines and other inflammatory mediators into the brain, and 
meta-analysis of studies has suggested that raised circulating inflammatory markers, 
including C-reactive protein (CRP) have an association with the subsequent development 
of depressive symptoms [2], and also influence the development and progression of 
major depressive disorders [3], and reduce the response to treatment [4]. 
Patients with CKD treated by dialysis have increased morbidity and mortality, 
and as dialysis does not replace normal kidney function, patients are required to comply 
with dietary and fluid restrictions, and a high pill burden. Although reports suggest 
that depression, is common amongst dialysis patients, with prevalence varying between 
39% based on self-reported screening and 23% based on psychiatric interview [5], and 
depressed haemodialysis patients are at greater risk of mortality [6]. However 
depression is more difficult to diagnose because of the overlap of symptoms between 
depression and those associated with end stage kidney disease [7].  
Although systemic inflammation, most commonly assessed by measuring CRP, is 
often present in haemodialysis patients, studies investigating a link between increased 
CRP and depressive symptoms in this population have been mixed, with some studies 
reporting a positive association [8,9], whereas others found no association [10,11]. To 
investigate whether there was an association between CRP and depressive symptoms we 
reviewed CRP results in a cohort of haemodialysis patients screened for depressive 
symptoms as part of the ASSERTID study [12], using the Beck Depression Inventory 
(BDII) [13] and Patient Health Questionnaire – 9 (PHQ-9) [14]. 
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Methods 
 396 patients from the Royal Free Hospital, north London and the Lister Hospital 
in Hertfordshire, UK were recruited into a screening trial for depression.    Patients 
established on haemodialysis for more 3 months were eligible to enter the study. There 
were no other exclusion criteria apart from the ability to read and understand English. 
Consenting patients completed Beck Depression Inventory (BDI-II) and Patient Health 
Questionnaire-9 (PHQ-9) [13,14] during their haemodialysis session. Previous work with 
this screening questionnaires for depression has recommended a cut off score of 16 or 
greater for the BDI-II and 10 or greater for the PHQ-9 for the diagnosis of self- 
reported depression [13,14]. Patient demographics and co-morbidity were recorded 
from computerised medical records.  
 Blood tests were taken routinely pre-dialysis on a monthly basis and results of 
haemoglobin, serum albumin, calcium, phosphate, CRP and calculation of dialysis 
adequacy by assessment of urea clearance (Kt/Vurea) closest to the day that 
questionnaires were completed were analysed. As two different methods were used to 
measure CRP (Royal Free Hospital (CRPL3, C-Reactive Protein Gen.3, Roche Cobas c 702, 
Roche Diagnostics, Berkhampstead, UK; Lister Hospital (immunoturbidimetric method, 
Olympus 2700 AU multi-analyser, Melville, New York, USA)),  we divided patients into 
those with a CRP within the normal reference range for both assays (1-5 mg/L) and 
those with an increased CRP (> 5 mg/L). 
 
Ethics 
 All patients provided appropriate informed consent in keeping with the Helsinki 
agreement, prior to receiving questionnaires. The study received ethical approval 
(National Research Ethics Service Committee London - Bentham, reference 
12/LO/1554), and was registered (ISRCTN06146268). 
 
Statistical analysis 
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 Data is reported as mean and standard deviation, or median and interquartile 
range, or percentage and intergroup analysis was by student’s t test, or Mann Whitney 
U test, or Chi square test with correction for repeated tests (Bonferroni or Dunn’s 
test) and for small numbers, where appropriate. Univariate association was with 
Spearman correlation. Multivariate linear regression for determinants of BDI-II and 
PHQ-9 were evaluated. Models were adjusted for variables which had a univariate 
relationship with the dependent variables, or thought to be clinically relevant 
determined a priori. These covariates were variables considered included;, age, sex, 
increased CRP (>5mg/L), diabetic status,  medical history of heart disease, amputation, 
stroke, cancer, ethnicity, months since starting HD, urine output, previous history of 
depression and serum albumin. Similarly logistic regression analysis was used to define 
determinants of high BDI-II. (≥16) and PHQ-9 (≥10) scores. These cut-offs were used 
based upon based validation studies of diagnosing depression in dialysis patients 
[15,16,17]. Analyses were performed with Graph Pad Prism (Graph Pad Prism V6.0, San 
Diego, USA) and SPSS 22 (SPSS 22, University Chicago, Illinois, USA). Statistical 
significance was taken as p<0.05. Tables presenting the regression analysis only show 
significantly variables in addition to CRP; although these were models were fully 
adjusted for the covariates described above. 
 
Results 
 396 patients were screened for depression and had CRP measured. 390 
completed the PHQ9 questionnaire, 389 the BDI-II. The mean age was 63.1 ±16.4 
years. 63.1% male. 197 were married or lived with a civil partner, 85 were single, 44 
divorced, 11 separated, and 55 widowed. The main ethnic groups were Caucasoid 235, 
South Asian 57, African-Afro-Caribbean 43 and East Asian 44. In terms of co-
morbidity 34.9% of patients were diabetic, 31.1% a history of heart disease, 11.4% 
malignancy, 8.5% chronic lung disease, 5.8% previous cerebrovascular disease and 3.5% 
amputation. Eighty eight patients (22.3%) had a past history of depression, 68 (17.2%) 
had been previously treated with antidepressants and 18 (4.5%) psychological therapy. 
Weight was 75.5±18.8 kg, with a mean arterial blood pressure pre dialysis of 99.4±16.5 
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and post-dialysis 92.3±16.4 mmHg. Mean haemoglobin was 111.1±12.1 g/l, serum albumin 
38.3±4.3 g/l, corrected calcium 2.28±0.20 mmol/l, phosphate 1.60±0.49 mmol/l, and 
median CRP 6 (5-15) mg/L.  The median BDI-II score was 10 (5-19), and PHQ-9 5 (2-
10), with 121 (31.1%) patients having a BDI score of ≥16, and 108 (27.8%) with a PHQ 
score of ≥10.  
 We divided patients into a normal CRP group (CRP ≤ 5 mg/L) and a high CRP group 
( > 5 mg/L). Groups were relatively well matched in terms of demographics (table 1), 
although the high CRP were older and had a greater number of Caucasoids, butCRP 
values were not statistically significantly different between the individual ethnic 
groups. The high CRP group had lower haemoglobin concentration and serum albumin 
(table 1). Although more patients with high CRPs were living alone, there were similar 
numbers of those divorced (normal CRP 18 vs high CRP 36), married or civil partnership 
(103 vs 94), single (46 vs 39), widowed (18 vs 37), X2=11.7, p=0.057. Education levels; no 
qualifications, school and university or other qualifications were similar between the 
groups (X2=3.5, p=0.83). 
There were no differences between the normal and high CRP groups in terms of 
previous history of depression, or treatments, and no significant differences between 
BDI-II, or PHQ9 scores (table 1).  
 
Adjusted regression models 
To investigate further whether there was an association between CRP and 
depression we first performed simple correlation analyses, and found no statistical 
association between serum CRP and either BDI-II and PHQ9 scores. We then 
constructed multivariable models incorporating those factors associated with BDI-II 
and PHQ9 scores (Tables 1 and 2). As there was no association with CRP (log 
transformed) as a continuous variable, we then chose to use a CRP cut off of > 5 mg/L. 
We found a positive association between the BDI-II score and previous history of 
depression, serum albumin, anuria and diabetes, and a negative association with age. An 
increased CRP (> 5 mg/L) was retained in the model, but failed to achieve statistical 
significance (p=0.057) (table 3). Similarly for PHQ9 there was an association with past 
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history of depression, serum albumin, anuria, diabetes, white ethnicity and increased 
CRP (table 4). We then performed binomial logistic, which demonstrated association 
between an increased BDI II score ≥ 16 and previous depression, age, serum albumin, 
anuria and also increased CRP (> 5mg/L) (table 5). . Those with a CRP>5 mg/l were 1.9 
times more likely to score ≥16 on the BDI-II (p=0.016). 
A similar model for increased PHQ9 (≥ 10), showed an association with past depression, 
serum albumin, but increased CRP was not statistically significant (table 6). 
 
Discussion 
 CRP production by the liver is increased in inflammatory states, and as such we 
expected to find an association between increasing CRP with a lower serum albumin and 
haemoglobin concentration. Many chronic diseases, including chronic heart failure, lung 
disease and rheumatoid arthritis, which impair physical function and activity are 
associated with increased prevalence of depressive symptoms are also associated with 
chronic inflammation and an increased serum CRP [2,3]. As such there is an association 
between increased CRP and depressive symptoms, but this does not necessarily infer 
causality [4].  
In keeping with earlier reports using screening questionnaires to determine the 
prevalence of depression in haemodialysis patient populations we found that 121 (31.1%) 
of patients had a BDI score of ≥16, and 108 (27.8%) a PHQ score of ≥10 [5,7,8]. These 
self-reported questionnaires have been previous validated and use a cut-off point of 
≥16 and ≥10 for the diagnosis of depressive symptoms [13,14]. Whereas previous studies 
using these and other screening questionnaires have variously reported a positive 
association between depression and increased CRP [8,9], or found no association [10,11]. 
Our study was larger than previous reports, and involved two centres; one serving an 
inner city London centre and the other outside London,  and we found no simple 
univariate association between serum CRP and depression using BDI-II, and PHQ-9 
screening questionnaires.  
Looking at individual components of the BDI-II score, we found increased 
reporting of changes in sleep pattern and appetite which overlap with symptoms 
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associated with CKD. As such our study highlights the difficulty of measuring 
depression in haemodialysis patients using screening questionnaires developed for the 
general population, due to the overlap of symptoms between depression and those 
associated with end stage kidney disease [7,16]. Many kidney dialysis patients complain 
of physical tiredness, mental fatigue and have reduced physical activity [18], which 
often do not improve following the initiation of dialysis therapy, and may even be made 
worse by haemodialysis treatments [19,20]. Patients with chronic kidney disease 
treated by haemodialysis are more likely to suffer protein energy wasting leading to 
muscle loss [21], and reduced muscle mass is associated with reduced physical activity 
and energy expenditure [22], so increasing weakness and fatigue. 
 
The BDI-II score was associated with younger age, higher serum albumin and 
anuria. The association between loss of residual renal function and depression has been 
reported previously [23].  Loss of residual renal function impacts on quality of life for 
the dialysis patient by increasing dietary and fluid restriction, coupled with potentially 
greater need for more dialysis therapy, in terms of longer duration of haemodialysis 
treatment sessions and more frequent attendance for dialysis. Hence the relationship 
between residual renal function and depression is not altogether surprising. Patients 
with both higher BDI-II and PHQ9 scores had been treated by haemodialysis for 
longer. Although there is an overlap between longer duration of dialysis and increased 
risk of loss of residual renal function, patients with longer dialysis vintage may have 
additional worries about failure to be transplanted and greater exposure to the 
complications of haemodialysis, in terms of vascular access failures and infections [24]. 
Our results are in keeping with previous smaller single centre reports, 
suggesting that younger healthier dialysis patients are more likely to self-report 
depressive symptoms, whereas older more co-morbid patients report fewer symptoms 
[23,25].  We also found an association with diabetes and increasing BDI-II score, this 
may be because both dialysis and diabetes impose restrictions on dietary intake, and on 
one hand dialysis impacts on diabetic control, and on the other residual renal function is 
often more rapidly lost with diabetic kidney disease [26]. Although an increased CRP 
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was retained in the model, CRP was not a significant independent factor. In a 
multivariable model using PHQ9 scores, we found similar associations to the BDI-II, 
although in this case an increased CRP was associated with increasing PHQ9 scores. On 
logistic regression though a high CRP was associated with a high BDI-II score (≥16) 
[13], the association with increased PHQ9 score (≥10) was not significant. There are 
some differences between the questionnaires, with 4 of the 9 PHQ-9 questions relating 
to difficulty with sleeping, lack of energy, poor appetite, moving slowly or having 
restlessness, which can be commonly reported by dialysis patients unrelated to 
depression. Whereas the BDI-II having 21 questions, with different scores relating to 
severity of replies, with 4 questions relating to difficulty with sleeping, lack of energy, 
fatigue and poor appetite. As such there may be a greater overlap between symptoms 
associated with chronic kidney disease [27] and the PHQ-9 compared to the BDI-II. 
Although the brain is protected by the blood-brain barrier, capillaries at the base of 
the median eminence are fenestrated, so permitting entry of inflammatory mediators 
into the area of the brain which controls appetite, and potentially alters mood and 
fatigue [28,29].  Our results support an earlier study showing an association between 
markers of inflammation and fatigue [27,30,], and this be due to the entry of 
inflammatory mediators into the brain [28]. 
 
 Self-reported depression is highly prevalent in chronic HD patients. However 
there is an overlap between some of the symptoms of chronic kidney failure and 
questions asked by the screening questionnaires for depression. Similarly chronic 
kidney disease is a pro-inflammatory condition and CRP concentrations are often 
increased in HD patients. As such we found that there was an association between an 
increased CRP and BDI-II score of ≥16, although the association was less than that for 
age, serum albumin, loss of residual renal function and diabetes. Our results are in 
keeping with those of a recent meta-analysis which shows that depression in advanced 
CKD is a heterogenous condition [31]. Since there is a crossover of symptoms between 
depression and advanced CKD,  and it is more likely that sicker patients, with 
combinations of inflammation, malnutrition and comorbidity who have greater CRP 
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values and a lower quality of Life, are potentially more likely to self-report depressive 
symptoms, and as such it may be that previous reports of a direct association between 
CRP and depression may have been confounded by the tools used for screening for 
depression, overestimating the effect of CRP. 
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Table 1.  Comparison of clinical and biochemical characteristics between those 
patients high (> 5mg/L) and normal CRP. Months of haemodialysis treatment (Vintage), 
dialysis sessional adequacy (Kt/Vurea). Results as numbers, or mean ± standard 
deviation, or median (interquartile range). 
 
 
 
Parameter N Normal CRP High CRP p-value 
number  191 205  
Age (years) 396 61 ± 18 65 ± 15 0.034 
% Male 396 62 64 0.591 
% White 396 52 66 0.004 
Vintage (months) 357 22 (9-50) 34(12-76) 0.008 
% Living Alone 392 28 37 0.043 
% Anuric 390 44 52 0.099 
% Diabetes 396 35 35 0.926 
% Heart Disease 396 26 36 0.043 
% Cancer 396 14 9 0.173 
Haemoglobin (g/L) 396 113 ± 12 110 ± 12 0.008 
Albumin (g/L)  396 39.3 ± 4.1 37.4 ± 4.3 <0.001 
Kt/Vurea 394 1.43 ± 0.30 1.37 ± 0.30 0.058 
Previous depression 396 39 49 0.251 
Previous antidepressants 396 27 41 0.158 
Previous psychotherapy 396 12 6 0.174 
BDI-II Score 389 9 (5-17) 11 (6-20) 0.076 
PHQ-9 Score 390 4 (2-9) 6 (2-10) 0.082 
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Table 2. Comparison of clinical and biochemical parameters in those patients with high 
(≥16) BDI-II and PHQ (≥10) scores and with lower levels. Months of haemodialysis 
treatment (Vintage), dialysis sessional adequacy (Kt/Vurea). Results as mean ±SD, or 
median (interquartile range) or percentage (%).* p<0.05, **<0.01, ***<0.001  BDI< 16 vs 
≥16 and PHQ9 <10 vs ≥10.  
 
 
Parameter N BDI <16 BDI ≥16 PHQ9 <10 PHQ9 ≥10 
Age (years) 385 65± 16*** 58 ± 16 65±16*** 60±16 
% Male 385 61 69 62 66 
% White 384 62 44 52* 42 
Vintage (months) 357 24 (9-56)* 40 (17-76) 25 (10-57)* 39 (14-76) 
% Living Alone 383 34 32 33 34 
% previous depression 385 13*** 57 15*** 42 
% Anuric 381 44* 57 45* 57 
% Diabetes 385 33 35 33 39 
% Heart Disease 385 31 31 31 32 
Haemoglobin (g/L) 385 111 ± 12 111 ± 12 111±12 110±12 
Albumin (g/L)  385 38.5 ± 4.2** 39.3 ± 4.3 38.1±4.3 38.8±4.5 
Kt/V 385 1.40 ± 0.28 1.38 ± 0.35 1.41±0.3 1.37±0.3 
% CRP > 5 mg/l 385 50 58 50 58 
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Table 3. Multivariable regression model for BDI-II scores adjusted for covariates 
(Tables 1 and 2; age, white ethnicity, heart disease, diabetes haemoglobin, albumin, 
anuria, past history of depression, living alone, dialysis vintage, CRP >5 mg/L).  Model fit 
r=0.54, r2 =0.25, adjusted r2 = 0.23, Durbin Watson 1.82. Standard error of β (StE β), 
exponential β (exp β), 95% confidence limits (5% CL and 95%CL). Past medical history 
(PMH), C reactive protein (CRP).  
 
variable β StE β Exp β t 5% CL 95% CL p 
PMH depression 10.8 1.32 0.40 8.2 8.2 13.4 <0.001 
Age years -0.10 0.04 -0.14 -2.6 -0.17 -0.25 0.009 
Albumin g/L 0.41 0.14 0.17 3.1 0.16 0.73 0.002 
Diabetes 2.7 1.24 0.11 2.2 0.22 5.1 0.033 
Anuria 2.4 1.15 0.11 2.1 1.46 4.72 0.037 
CRP > 5 mg/L 2.2 1.14 0.10 1.9 0.67 4.41 0.057 
 
 
 
 
 
 
 
 
Table 4. Multivariable regression model for PHQ9 score adjusted for covariates 
(Tables 1 and 2).  Model fit r=0.47, r2 =0.252 adjusted r2 = 0.20, Durbin Watson 1.97. 
Standard error of β (StE β), exponential β (exp β), 95% confidence limits (5% CL and 
95%CL). Past medical history (PMH), C reactive protein (CRP).  
 
variable β StE β Exp β t 5% CL 95% CL p 
PMH depression 5.3 0.69 0.38 7.6 3.93 6.68 <0.001 
Albumin g/L 0.2 0.08 0.15 2.7 0.06 0.36 0.006 
Anuria 1.3 0.62 0.11 2.1 0.10 2.52 0.034 
Diabetes 1.3 0.66 0.11 2.9 0.05 2.63 0.042 
White ethnicity 1.3 0.64 0.11 2.0 0.04 2.56 0.043 
CRP > 5 mg/L 1.2 0.60 0.10 2.0 0.02 2.39 0.046 
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Table 5.  Logistic regression model for BDI-II score ≥16 adjusted for covariates 
(Tables 1 and 2).  Model fit Nagelkerke r2 = 0.26. Standard error of β (StE β), 
exponential β (exp β), 95% confidence limits exp β (5% CL and 95%CL). Past medical 
history (PMH), C reactive protein (CRP).  
 
variable β StE β Wald Exp β 5% CL 95% CL p 
PMH depression 1.6 0.30 3.2 5.1 2.84 9.03 <0.001 
Albumin g/L 0.1 0.04 12.7 1.1 1.06 1.22 <0.001 
Age years -0.1 0.01 5.7 0.9 0.96 0.99 0.017 
CRP > 5 mg/L 0.7 0.28 5.8 1.9 1.13 3.34 0.016 
 
 
 
 
 
 
Table 6.  Logistic regression model for PHQ9 score ≥10 adjusted for covariates (Tables 
1 and 2).  Model fit Nagelkerke r2 = 0.20. Standard error of β (StE β), exponential β 
(exp β), 95% confidence limits exp β (5% CL and 95%CL). Past medical history (PMH), C 
reactive protein (CRP).  
 
variable β StE β Wald Exp β 5% CL 95% CL p 
PMH depression 1.5 0.29 26.9 4.6 2.58 8.1 <0.001 
Albumin g/L 0.7 0.04 4.2 1.1 1.00 1.15 0.04 
CRP > 5 mg/L 0.4 0.46 2.4 1.5 0.89 2.63 0.12 
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